Why the study?
The study evaluated subclinical cardiotoxicity across two anthracycline-containing chemotherapy regimens in breast cancer patients with normotension and arterial hypertension.
Does a higher cumulative dose of doxorubicin (320 mg/m2) increase subclinical cardiotoxicity compared to a lower dose (200 mg/m2) in women with triple negative breast cancer?
Does a higher cumulative dose of doxorubicin (320 mg/m2) increase subclinical cardiotoxicity compared to a lower dose (200 mg/m2) in women with triple negative breast cancer?
Answers are grounded in this paper and cite their sources.
Higher cumulative doses of doxorubicin (320 mg/m2) in breast cancer patients are associated with significant increases in biomarkers of myocardial damage compared to lower doses.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Avalyan et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: